

Lund, Sweden, December 6, 2023



Hamlet BioPharma’s continued development of brain tumor therapy

Hamlet BioPharma AB (publ), the pharmaceutical company with a strong portfolio of projects for the treatment of cancer and infections, shares an update today about the development of brain tumor therapy based on the investigational new drug Alpha1H. Hamlet BioPharma together with its partner Neurochase Ltd. are making progress with the early pre-clinical work for the treatment of brain tumors. Important milestones have been reached during the preclinical assessment.

Hamlet BioPharma is developing a new class of anti-cancer therapeutics for multiple cancer indications based on the discovery of its proprietary drug complex HAMLET (‘Human Alpha-lactalbumin Made Lethal to Tumor cells’). HAMLET has shown great promise for the treatment of brain tumors, killing brain tumor cells of different origins and significantly delaying brain tumor growth. The cellular effects are reproduced by Hamlet BioPharma’s lead anti-cancer compound Alpha1H, which efficiently kills different brain tumor cells in the laboratory.

The brain and spinal cord constitute the central nervous system (CNS), where vital functions are controlled. Due to a lack of efficient drugs that are suitable for delivery into the central nervous system, brain tumor treatment presents a significant challenge. Unlike other organs, the brain does not easily tolerate invasive procedures, making surgical removal of tumors particularly difficult. In many cases, the location of tumors within the brain may render them inoperable without causing severe damage to vital neural structures.

Collaboration - Hamlet BioPharma and Neurochase Limited explore technology for delivery of Alpha1H into the brain

The protective blood-brain barrier blocks drugs in the blood from entering the brain. Alternative methods therefore explore drug delivery to precise locations in the brain, where the tumors are localized. Delivery technology suitable for Alpha1H is being developed in collaboration with Professor Gill, who is a world leader in this field. The collaboration between Hamlet BioPharma and Neurochase Limited combines a new technology for drug delivery developed by Neurochase and Hamlet BioPharma’s drug candidate Alpha1H. The collaboration will focus on the technology and initially explore infusion of Alpha1H in an animal model, in preparation for clinical trials. Both companies believe that the delivery of Alpha1H by the Neurochase delivery system has the potential to be developed for the

treatment of patients with primary brain tumors or metastases from cancers in peripheral organs.

Important milestones reached during the preclinical assessment include studies of compatibility of Alpha1H with the infusion device, lack of toxicity and useful pharmacology studies.

For more detailed information, please visit our website or sign-up for our newsletter at: <https://hamletbiopharma.com/subscribe/>

For further information, please contact:

Catharina Svanborg, Chairman and Founder of Hamlet BioPharma, +46-709 42 65 49
catharina.svanborg@hamletpharma.com

Martin Erixon, CEO Hamlet BioPharma, +46-733 00 43 77
martin.erixon@hamletpharma.com

www.hamletbiopharma.com